Spexis Past Earnings Performance
Past criteria checks 0/6
Spexis's earnings have been declining at an average annual rate of -54.4%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 111.4% per year.
Key information
-54.4%
Earnings growth rate
60.2%
EPS growth rate
| Biotechs Industry Growth | 18.9% |
| Revenue growth rate | 111.4% |
| Return on equity | -72.3% |
| Net Margin | -1,068.7% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Spexis makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 1 | -12 | 6 | 9 |
| 31 Mar 23 | 1 | -16 | 7 | 11 |
| 31 Dec 22 | 1 | -19 | 7 | 13 |
| 30 Sep 22 | 1 | -20 | 7 | 10 |
| 30 Jun 22 | 1 | -21 | 7 | 7 |
| 31 Mar 22 | 0 | -16 | 5 | 4 |
| 31 Dec 21 | 0 | -12 | 3 | 1 |
| 30 Sep 21 | 0 | -7 | 2 | 1 |
| 30 Jun 21 | 0 | -2 | 1 | 1 |
| 31 Mar 21 | 0 | -2 | 1 | 1 |
| 31 Dec 20 | 0 | -2 | 1 | 1 |
| 31 Dec 19 | 0 | -2 | 1 | 0 |
Quality Earnings: SPEX is currently unprofitable.
Growing Profit Margin: SPEX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SPEX is unprofitable, and losses have increased over the past 5 years at a rate of 54.4% per year.
Accelerating Growth: Unable to compare SPEX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SPEX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: SPEX has a negative Return on Equity (-72.28%), as it is currently unprofitable.